Tecentriq®

Understanding Tecentriq® 

Tecentriq® (atezolizumab) is an FDA-approved monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), a protein that allows cancer cells to evade the immune system. By blocking PD-L1, Tecentriq® enhances the body’s immune response against cancer cells. It is utilized in the treatment of various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS).

How Tecentriq® Works:

• Immune System Activation: Atezolizumab binds to PD-L1, preventing it from interacting with PD-1 receptors on T-cells. This blockade restores T-cell activity, enabling the immune system to recognize and attack tumor cells.

• Combination Therapies: Tecentriq® is often used in combination with other treatments, such as bevacizumab, chemotherapy agents, or targeted therapies, to enhance its anti-tumor efficacy.

• Administration: Traditionally administered intravenously, Tecentriq® is given over a period of time, with dosing schedules varying based on the specific cancer type and treatment regimen. A subcutaneous formulation, Tecentriq Hybreza™, has also been approved to provide a more convenient administration option.

FDA Approval:

• Tecentriq® received its initial FDA approval on May 18, 2016, for the treatment of urothelial carcinoma. Subsequent approvals have expanded its indications to include NSCLC, SCLC, HCC, melanoma, and ASPS. The subcutaneous formulation, Tecentriq Hybreza™, was approved on September 12, 2024.

For more information, please visit the Tecentriq® patient website and speak with your healthcare provider to determine if Tecentriq® is the right treatment option for you.